Allelic frequency of PON1 Q192R, CYP2C19*2 and CYP2C19*17 among Jordanian patients taking clopidogrel

被引:5
作者
Rjoub, Malek [1 ]
Saleh, Akram [2 ]
Hakooz, Nancy [3 ]
Imraish, Amer [4 ]
Jarrar, Yazun [5 ]
Zihlif, Malek [1 ]
机构
[1] Univ Jordan, Fac Med, Dept Pharmacol, Amman, Jordan
[2] Univ Jordan, Dept Internal Med, Univ Jordan Hosp, Amman, Jordan
[3] Univ Jordan, Dept Biopharmaceut & Clin Pharm, Fac Pharm, Amman, Jordan
[4] Univ Jordan, Dept Biol, Fac Sci, Amman, Jordan
[5] AlZaytoonah Univ Jordan, Coll Pharm, Dept Pharm, Amman, Jordan
关键词
CYP2C9; polymorphisms; Clopidogrel; Genotype; Allele frequency; PON1; genes; GENETIC-POLYMORPHISM; GENOTYPE FREQUENCIES; CYP2C19; PHARMACOGENETICS; PARAOXONASE-1; PHENOTYPE; VARIANT; 2C19;
D O I
10.4314/tjpr.v17i11.24
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose: To investigate the influence of allelic frequencies of PON1 Q192R, CYP2C19*2 and CYP2C19*17 genetic polymorphisms on the response to clopidogrel among Jordanian patients. Methods: Polymorphisms in CYP2C19 were assessed among 148 patients using PCR-RFLP assay. Results: The CYP2C19*2, CYP2C19*17, and PON1 Q192R allele frequencies were 9.8, 28.72 and 28.7 %, respectively. On the genotyping side, the frequencies of CYP2C19*1/1* and CYP2C19*1/2* were 80.4 and 19.6 %, respectively, but none of the patients had CYP2C19*2/2* genotype. The genotype frequencies CYP2C19*17 were 47.97, 46.62 and 5.41 % for wild-type C-C, heterozygote C-T, and the mutant T-T, respectively. PON1 genotype was 42.7 % for QQ, and 57.8 % for QR. None of the patients had RR genotype. Conclusion: Relative to other populations, the observed allelic frequencies are consistent with the values reported for Caucasian and Middle Eastern populations.
引用
收藏
页码:2275 / 2280
页数:6
相关论文
共 25 条
  • [11] Sequence analysis of the N-acetyltransferase 2 gene (NAT2) among Jordanian volunteers
    Jarrar, Yazun Bashir
    Balasmeh, Ayat Ahmed
    Jarrar, Wassan
    [J]. LIBYAN JOURNAL OF MEDICINE, 2017, 13
  • [12] Lee Su-Jun, 2013, Frontiers in Genetics, V3, P318, DOI 10.3389/fgene.2012.00318
  • [13] Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17
    Li-Wan-Po, Alain
    Girard, Thierry
    Farndon, Peter
    Cooley, Candy
    Lithgow, James
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 69 (03) : 222 - 230
  • [14] Genetic polymorphism of cytochrome P4502C19 in Mexican Americans: A cross-ethnic comparative study
    Luo, Huai-Rong
    Poland, Russell E.
    Lin, Keh-Ming
    Wan, Yu-Jui Yvonne
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 80 (01) : 33 - 40
  • [15] Linkage disequilibrium between the CYP2C19*17 allele and wildtype CYP2C8 and CYP2C9 alleles: identification of CYP2C haplotypes in healthy Nordic populations
    Pedersen, Rasmus S.
    Brasch-Andersen, Charlotte
    Sim, Sarah C.
    Bergmann, Troels K.
    Halling, Jonrit
    Petersen, Maria S.
    Weihe, Pal
    Edvardsen, Hege
    Kristensen, Vessela N.
    Brosen, Kim
    Ingelman-Sundberg, Magnus
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 66 (12) : 1199 - 1205
  • [16] Genotype-Phenotype Analysis of CYP2C19 in Healthy Saudi Individuals and its Potential Clinical Implication in Drug Therapy
    Saeed, Leena H.
    Mayet, Ahmed Y.
    [J]. INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, 2013, 10 (11): : 1497 - 1502
  • [17] Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population
    Scordo, MG
    Caputi, AP
    D'Arrigo, C
    Fava, G
    Spina, E
    [J]. PHARMACOLOGICAL RESEARCH, 2004, 50 (02) : 195 - 200
  • [18] Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450-2C19 (CYP2C19) Genotype and Clopidogrel Therapy
    Scott, S. A.
    Sangkuhl, K.
    Gardner, E. E.
    Stein, C. M.
    Hulot, J-S
    Johnson, J. A.
    Roden, D. M.
    Klein, T. E.
    Shuldiner, A. R.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 90 (02) : 328 - 332
  • [19] Association of Cytochrome P450 2C19 Genotype With the Antiplatelet Effect and Clinical Efficacy of Clopidogrel Therapy
    Shuldiner, Alan R.
    O'Connell, Jeffrey R.
    Bliden, Kevin P.
    Gandhi, Amish
    Ryan, Kathleen
    Horenstein, Richard B.
    Damcott, Coleen M.
    Pakyz, Ruth
    Tantry, Udaya S.
    Gibson, Quince
    Pollin, Toni I.
    Post, Wendy
    Parsa, Afshin
    Mitchell, Braxton D.
    Faraday, Nauder
    Herzog, William
    Gurbel, Paul A.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2009, 302 (08): : 849 - 858
  • [20] Cytochrome 2C19*17 Allelic Variant, Platelet Aggregation, Bleeding Events, and Stent Thrombosis in Clopidogrel-Treated Patients With Coronary Stent Placement
    Sibbing, Dirk
    Koch, Werner
    Gebhard, Daniela
    Schuster, Tibor
    Braun, Siegmund
    Stegherr, Julia
    Morath, Tanja
    Schoemig, Albert
    von Beckerath, Nicolas
    Kastrati, Adnan
    [J]. CIRCULATION, 2010, 121 (04) : 512 - 518